<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572621</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0010</org_study_id>
    <nct_id>NCT03572621</nct_id>
  </id_info>
  <brief_title>Development and Evaluation of a Therapeutic Education Intervention in Prostate Cancer Patients Treated With Radical Prostatectomy to Improve Their Sexuality</brief_title>
  <acronym>PRODUCAN</acronym>
  <official_title>Development and Evaluation of a Therapeutic Education Intervention in Prostate Cancer Patients Treated With Radical Prostatectomy to Improve Their Sexuality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prostate cancer is the most common cancer in France (54,000 cases in 2011). About 20,000&#xD;
      radical prostatectomies (PR) per year are performed. Despite the progress of PR over the past&#xD;
      20 years, the rate of erectile dysfunction post PR varies between 30 and 90% and only 16% of&#xD;
      operated men recover their pre-treatment erections.&#xD;
&#xD;
      There is currently no validated post-prostatectomy rehabilitation protocol. The associations&#xD;
      of patients, including the National Association of Prostate Cancer Patients have a very&#xD;
      strong demand for treatment of sexual problems after treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change the quality of sexual life of patients treated with radical prostatectomy (PR)</measure>
    <time_frame>18 months</time_frame>
    <description>Comparison of the difference in self-Esteem quotation and Relationship (SEAR) questionnaire, between the experimental group and control, between inclusion and Month 18.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sexual function</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
    <description>Measure of The International Index of Erectile Function (IIEF-EF) score. This validated score measures the erectile component.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General quality of life</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
    <description>Signing of questionnaire EuroQol-D5 (EQ-D5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sexual quality of life of the partner</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
    <description>Index of Sexual Life (ISL) questionnaire, validated questionnaire specifically created to assess the impact of erectile dysfunction (ED) in the partner.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of erections obtained in the last month</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
    <description>Patient questionnaire to be filled every month at home by the patient and the partner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of reports deemed satisfactory</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
    <description>Patient questionnaire to be filled every month at home by the patient and the partner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intracavernous injections performed per week</measure>
    <time_frame>Month18</time_frame>
    <description>Patient questionnaire to be filled every month at home by the patient and the partner</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Activation Measure (questionnaire PAM)</measure>
    <time_frame>Month18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erection Hardness Score (EHS)</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continence: urinary handicap measurement scale (MHU)</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Penis size (cm)</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge acquisition measured by quizz build for the study made of simulated cases</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acquisition of sexual intercourse management skills measured by quizz build for the study made of simulated cases</measure>
    <time_frame>Month 1, 6, 12 and 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety level measured by the Hospital Anxiety and Depression (HAD) scale</measure>
    <time_frame>Month 6 and18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression level measured by the Hospital Anxiety and Depression (HAD) scale</measure>
    <time_frame>Month 6 and18</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental group are offered to participate in a 6-session therapeutic education program on sexuality, ranging from 15 days before surgery to approximately 3 months after. This in addition to the current care by the teams of care about sexual rehabilitation (information and medication prescriptions).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patient without therapeutic education.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Partner</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient's partner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Therapeutic education</intervention_name>
    <description>Patients will benefit from the first session of preoperative therapeutic education, then the next 5 sessions will be done postoperatively over a period of 4 month and a half.&#xD;
Session 1: The first session will be devoted appropriately to patient education. It will take place on the day of the preoperative anesthesia consultation.&#xD;
Session 2: day of discharge from hospital. Make the patient adhere to the concept of post PR erectile rehabilitation in the same way as sphincter reeducation.&#xD;
Session 3: Presentation of available treatments, start intracavernous injections.&#xD;
Session 4: Acquisition of know-how on treatment management. Reduce anxiety. Session 5: Encourage the resumption of intercourse very gradually. The presence of the partner will be advised.&#xD;
Session 6: measure of the evolution of the representations and knowledge of the patient. The skills of the patient will be evaluated from problem situations, motivation scale. The know-how will be evaluated using observation grid.</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of data concerning their sexuality</intervention_name>
    <description>Patients in the control group are offered to participate in the study, which consists of collecting data on their sexuality. This in addition to the current care by the teams of care about erectile rehabilitation (information and medication prescriptions).</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Participation</intervention_name>
    <description>Participation in a therapeutic education day.</description>
    <arm_group_label>Partner</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients treated in urology consultation at the University Hospital of Lyon Sud or Edouard&#xD;
        Herriot:&#xD;
&#xD;
          -  Aged over 18&#xD;
&#xD;
          -  presenting a cancerous pathology of the prostate having an indication of radical&#xD;
             prostatectomy with or without preservation of the neurovascular strips.&#xD;
&#xD;
          -  Having a normal preoperative erectile function defined by an EF (International Index&#xD;
             of Erectile Function) score ≥ 26&#xD;
&#xD;
          -  affiliated to a social security scheme.&#xD;
&#xD;
          -  and having been informed and given informed consent to participation in the program.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Preoperative score IIEF EF &lt;26&#xD;
&#xD;
          -  Refusal of participation, signature of consent,&#xD;
&#xD;
          -  protected major patients, under guardianship or curators.&#xD;
&#xD;
          -  Patients unable to understand the course of the study&#xD;
&#xD;
          -  Patient with a documented history of cognitive or psychiatric disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patients treated in urology consultation at the University Hospital of Lyon Sud or Edouard Herriot Hospital for a Prostatectomy</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Etienne TERRIER, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damien CARNICELLI, MD</last_name>
    <phone>04 72 67 88 01</phone>
    <phone_ext>+33</phone_ext>
    <email>damien.carnicelli@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Hédouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CUZIN Béatrice, MD</last_name>
    </contact>
    <investigator>
      <last_name>Béatrice CUZIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc COLOMBEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lionel BADET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien CROUZET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien CARNICELLI, MD</last_name>
      <email>damien.carnicelli@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Damien CARNICELLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas MOREL-JOURNEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alain RUFFION, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 4, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostatectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

